Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for treating cardiovascular and cerebrovascular diseases

A technology of cardiovascular and cerebrovascular diseases and compositions, applied in the field of medicine, can solve problems such as unknown specific mechanism and adverse reactions, and achieve the effect of promoting absorption in the body and easy sticking

Inactive Publication Date: 2009-05-13
张蔚
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019]7. Radiation protection: patients with malignant tumors often need radiation therapy, and radiation therapy can cause serious adverse reactions
But oral administration did not find this effect, and the specific mechanism is unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Embodiment 1 Feeding ratio and preparation method

[0055] Hydroxypropylmethylcellulose (HPMC) 0%-2% or low-substituted hydroxypropylcellulose (L-HPC) 0%-2%, starch 1%-2%, sodium lauryl sulfate 0.5%- 1%, lactose 15%-20%, microcrystalline cellulose 8%-11%, calcium hydrogen phosphate 10%-18%, micronized silica gel 1%-2%, magnesium stearate 0%-2%, talc 0 %-2% (in the specific prescription, magnesium stearate and talc can only have a ratio of 0%), sodium carboxymethyl starch (DST) 5%-7%, pantethine and probucol The dosage should ensure that each tablet or capsule contains 30 mg and 125 mg respectively.

[0056] Lactose, starch, microcrystalline cellulose, calcium hydrogen phosphate, DST, micronized silica gel, magnesium stearate and / or talc are passed through a 80-mesh sieve, and the coarse powder is discarded. Repeatedly stir the prescribed amount of probucol, lactose, microcrystalline cellulose, calcium hydrogen phosphate, and half the prescribed amount of DST into a un...

Embodiment 2

[0057] Embodiment 2 Feeding ratio and preparation method

[0058] HPMC 1%, Starch 1%, Sodium Lauryl Sulfate 0.5%, Lactose 15%, Microcrystalline Cellulose 8%, Calcium Hydrogen Phosphate 10%, Micronized Silica Gel 1%, Magnesium Stearate 1%, DST 5%, The dosage of pantethine and probucol should be ensured that each tablet or capsule contains 30 mg and 70 mg respectively.

[0059] Lactose, starch, microcrystalline cellulose, calcium hydrogen phosphate, DST, micronized silica gel, and magnesium stearate are passed through an 80-mesh sieve, and the coarse powder is discarded. Repeatedly stir the prescribed amount of probucol, lactose, microcrystalline cellulose, calcium hydrogen phosphate, and half the prescribed amount of DST into a uniform powder mixture. Stir it with 8 times the total amount of sodium lauryl sulfate, pantethine, and half the prescription amount of DST until it is completely dissolved. Disperse it evenly with 95% ethanol of 10 times the amount of HPMC prescriptio...

Embodiment 3

[0060] Embodiment 3 Feeding ratio and preparation method

[0061] L-HPC 2%, Starch 2%, Sodium Lauryl Sulfate 1%, Lactose 20%, Microcrystalline Cellulose 11%, Dicalcium Phosphate 18%, Micronized Silica Gel 2%, Talc 2%, DST 7%. The dosage of pantethine and probucol should be ensured that each tablet or capsule contains 10 mg and 20 mg respectively.

[0062]Lactose, starch, microcrystalline cellulose, calcium hydrogen phosphate, DST, micronized silica gel, and talcum powder are passed through an 80-mesh sieve, and the coarse powder is discarded. Repeatedly stir the prescribed amount of probucol, lactose, microcrystalline cellulose, calcium hydrogen phosphate, and half the prescribed amount of DST into a uniform powder mixture. Stir it with 10 times the total amount of sodium lauryl sulfate, pantethine, and half the prescription amount of DST in the prescription until they are completely dissolved. Use 15 times the absolute ethanol of the L-HPC prescription amount to disperse it...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. The pharmaceutical composition comprises pantomin and probucol succinic monoester. Pantomin, rather than probucol or probucol succinic monoester, has the effects of reducing triglyceride; therefore, the compounding of the two drugs can realize complementary action.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. Background technique [0002] Pantethine, probucol or probucol monosuccinate sodium are both cardiovascular and cerebrovascular drugs, and their efficacy and mechanism of action are different. In its non-patent literature, there is no report of its compound preparation, only the report of the combined use of pantethine and probucol: TokushigeK et al.Hepatol Res, 2007; 37 (10): 872-7 reported that probucol The combination of Buco and pantethine has obvious synergistic effect on serum lipoprotein metabolism and atherosclerosis in rabbits. Tawara K et al.Jpn J Pharmacol, 1986; 41(2): 211-22 reported that the combination of the two is safe and effective for Japanese patients with non-alcoholic fatty liver. So far, neither its compound preparation nor its combination drug patent liter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/16A61K31/10A61P9/00A61P9/10A61P3/06
Inventor 方树青
Owner 张蔚
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com